Technical quality assurance during the TROG 03.04 RADAR prostate radiotherapy trial: Are the results reflected in observed toxicity rates?

Martin Ebert, M.K. Bulsara, A. Haworth, R. Kearvell, Sharon Richardson, A.M. Kennedy, Nigel Spry, Sean Bydder, David Joseph, J.W. Denham

    Research output: Contribution to journalArticle

    2 Citations (Scopus)
    94 Downloads (Pure)

    Abstract

    © 2014 The Royal Australian and New Zealand College of Radiologists. Introduction Multicentre radiotherapy clinical trials can incorporate quality assurance (QA) procedures for ensuring consistent application of the trial protocol in the planning, delivery and reporting of participant treatments. Subsequently detected variations from trial protocol have previously been shown to reduce treatment efficacy, although little has been shown for toxicity rates. The purpose of this study was to investigate the association of QA measures and protocol variations on toxicity incidence in the context of a prostate radiotherapy trial. Methods Using QA records from the TROG 03.04 RADAR trial, the impact of variations on gastrointestinal (GI) and genito-urinary (GU) toxicities was investigated. Results Protocol variation rates were lower than reported in previous studies, and showed little correlation with GI toxicity outcomes. Variations classified as 'major' showed a non-significant trend for increased toxicity relative to those classified as 'minor'. Results from a Level III phantom-based dosimetry study showed some correlation with GI toxicity, whereas ranking on a set-up accuracy study did not impact on toxicity. Toxicity in general increased with the number of participants accrued per centre, at odds with previous reports relating to disease progression, with a potential link to increases in low-mid-range rectal doses in the cohort from higher-accruing centres. No QA-related variables correlated with GU toxicities. Conclusions Besides non-significant trends, minimal association was observed between QA variables and toxicity rates for the RADAR trial. The intention of the trial's QA programme was to reduce treatment variations and minimise toxicity in the context of a relevantly advanced treatment approach.
    Original languageEnglish
    Pages (from-to)99-108
    Number of pages10
    JournalJournal of Medical Imaging and Radiation Oncology
    Volume59
    Issue number1
    DOIs
    Publication statusPublished - 28 Jan 2015

    Fingerprint Dive into the research topics of 'Technical quality assurance during the TROG 03.04 RADAR prostate radiotherapy trial: Are the results reflected in observed toxicity rates?'. Together they form a unique fingerprint.

  • Cite this